Teva Pharmaceutical Industries Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TEVA research report →
Companywww.tevapharm.com
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients.
- CEO
- Richard D. Francis
- IPO
- 1982
- Employees
- 37,000
- HQ
- Tel Aviv, IL
Price Chart
Valuation
- Market Cap
- $39.96B
- P/E
- 25.46
- P/S
- 2.32
- P/B
- 4.83
- EV/EBITDA
- 16.17
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 51.98%
- Op Margin
- 19.38%
- Net Margin
- 9.03%
- ROE
- 20.79%
- ROIC
- 11.49%
Growth & Income
- Revenue
- $17.26B · 4.31%
- Net Income
- $1.41B · 186.03%
- EPS
- $1.23 · 184.83%
- Op Income
- $2.16B
- FCF YoY
- 53.27%
Performance & Tape
- 52W High
- $37.35
- 52W Low
- $14.99
- 50D MA
- $31.82
- 200D MA
- $27.03
- Beta
- 0.86
- Avg Volume
- 6.69M
Get TickerSpark's AI analysis on TEVA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Lippman Evan | other | 74,008 |
| May 14, 26 | Lippman Evan | other | 74,008 |
| May 14, 26 | Lippman Evan | sell | 35,912 |
| May 14, 26 | Lippman Evan | other | 11,841 |
| May 14, 26 | Lippman Evan | other | 11,841 |
| May 14, 26 | Lippman Evan | sell | 5,746 |
| May 14, 26 | Kalif Eliyahu Sharon | sell | 153,251 |
| May 6, 26 | Weiss Amir | sell | 10,679 |
| May 5, 26 | Daniell Richard | sell | 30,000 |
| May 1, 26 | Sabag Mark | sell | 144,180 |
Our TEVA Coverage
We haven't published any research on TEVA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TEVA Report →